Drug-resistant mycobacterial infections are a serious global health challenge, leading to
high mortality and socioeconomic burdens in developing countries worldwide. New …

Mycobacterium tuberculosis (Mtb) can withstand months of antibiotic treatment. An important
goal of tuberculosis research is to shorten the treatment to reduce the burden on patients …

The spread of antimicrobial resistance has become a serious public health concern, making
once-treatable diseases deadly again and undermining the achievements of modern …

The use of efflux pump inhibitors (EPIs) as potentiators along with the traditional antibiotics
assists in the warfare against antibiotic-resistant superbugs. Efflux pumps of the resistance …

Tuberculosis (TB) is among the most difficult infections to treat, requiring several months of
multidrug therapy to produce a durable cure. The reasons necessitating long treatment times …

Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium
tuberculosis, was the leading cause of mortality worldwide in 2019 due to a single infectious …

The emergence of multi-and extensively drug resistant tuberculosis worldwide poses a great
threat to human health and highlight the need to discover and develop new, effective and …

Tuberculosis treatment requires months-long combination chemotherapy with multiple
drugs, with shorter treatments leading to relapses. A major impediment to shortening …

The global spread of microbial resistance coupled with high costs and slow pace in the
discovery of a new antibiotic have made drug repositioning an attractive and promising …

Development of novel anti-tuberculosis combination regimens that increase efficacy and
reduce treatment timelines will improve patient compliance, limit side-effects, reduce costs …